tiprankstipranks

Anixa Biosciences initiated with a Buy at EF Hutton

EF Hutton initiated coverage of Anixa Biosciences with a Buy rating and $10 price target. Anixa is a biotechnology company that harnesses the immune system to fight cancer, the analyst tells investors in a research note. The firm says the company’s lead program involves developing a CAR-T therapy targeting solid tumors. The company is also developing cancer vaccines, including one for triple-negative breast cancer and another for ovarian cancer, EF points out.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue